Cargando…
1149. Baseline Chest CT Findings in Patients with Pulmonary Mold Infections: A Post-Hoc Analysis from the Phase 3 SECURE Study that Compared Isavuconazole to Voriconazole for the Primary Treatment of Invasive Mold Disease
BACKGROUND: SECURE was a global, double-blind, Phase 3 study that randomized 527 patients 1:1 to isavuconazole (ISAV) or voriconazole (VORI) for the primary treatment of invasive mold disease (IMD) caused by Aspergillus or other filamentous fungi. Patients were classified as having proven/probable I...
Autores principales: | Hamed, Kamal, Engelhardt, Marc, Saulay, Mikael, Kovanda, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777367/ http://dx.doi.org/10.1093/ofid/ofaa439.1335 |
Ejemplares similares
-
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies
por: Hamed, Kamal, et al.
Publicado: (2023) -
850. Real-world effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients
por: Qiu, Ye, et al.
Publicado: (2023) -
Isavuconazole for COVID-19-Associated Invasive Mold Infections
por: Ullah, Nadir, et al.
Publicado: (2022) -
Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response
por: Kovanda, Laura L., et al.
Publicado: (2017) -
Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases
por: Kaindl, Thomas, et al.
Publicado: (2019)